Skip to main content

Site notifications

Notice for olipudase alfa (Sanofi-Aventis Australia Pty Ltd)

Active ingredients
olipudase alfa
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Treatment of Acid sphingomyelinase deficiency (ASMD)
Therapeutic area
Inherited metabolic disorders

Help us improve the Therapeutic Goods Administration site